Alise Dozier
Nurse Practitioner · Alexandria, LANPI 1053744516
Payments from drug & device makers
Across 42 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$319
- Novartis$110
- OPKO Pharmaceuticals, LLC$57
- Otsuka America Pharmaceutical, Inc.$54
- Scpharmaceuticals Inc.$54
- Calliditas Therapeutics US Inc.$38
- plus $191 from 8 others
What the payments were for
- Food & beverage$76693%
- Education$577%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 17 | $319 |
| Novartis | 4 | $110 |
| OPKO Pharmaceuticals, LLC | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Scpharmaceuticals Inc. | 3 | $54 |
| Calliditas Therapeutics US Inc. | 2 | $38 |
| Bayer | 2 | $34 |
| AstraZeneca | 2 | $33 |
| Amgen | 2 | $32 |
| Ardelyx, Inc. | 1 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
| Cormedix Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 1 | $11 |
How this compares
$823 in reported general payments places this provider in the 65th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 51 | $16,358 |
| LinzessLinaclotide | 13 | $7,362 |
| XareltoRivaroxaban | 24 | $6,779 |
| JanuviaSitagliptin Phosphate | 13 | $3,839 |
| Potassium Chloride | 62 | $1,179 |
| Carbamazepine | 55 | $1,136 |
| Levothyroxine Sodium | 96 | $929 |
| Novolog FlexpenInsulin Aspart | 25 | $897 |
| Megestrol Acetate | 31 | $870 |
| Midodrine Hcl | 21 | $776 |
| Gemfibrozil | 59 | $638 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 17 | $575 |
| Sevelamer Carbonate | 11 | $487 |
| Atorvastatin Calcium | 55 | $468 |
| Sertraline Hcl | 66 | $466 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Alexandria
- Reghan LittlepageAlexandria$24K
- Kasey GillAlexandria$9K
- Mary GarciaAlexandria$8K
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Teri DugganBossier City$67K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.